Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative docetaxel + oxaliplatin + 5-fluorouracil + folinic acid for resectable gastric and gastroesophageal junction adenocarcinoma
2008-007546-56Phase 2Completed
- Sponsor
- LMU Klinikum
- Start
- Aug 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, oxaliplatin, fluorouracil and folinic acid in gastroesophageal junction adenocarcinoma and gastric adenocarcinoma, sponsored by LMU Klinikum. Primary endpoint: Completion of surgery after 6 cycles of treatment. Started Aug 2009; status: completed.
02
Drugs
docetaxeloxaliplatinfluorouracilfolinic acid
03
Conditions
gastroesophageal junction adenocarcinomagastric adenocarcinoma
Beyond the preview
Go deeper on 2008-007546-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007546-56.